PacBio’s newly formalized distribution agreement with Haorui Gene is focused on accelerating the adoption of HiFi long-read sequencing technology across clinical and research settings in China ...

With the improvements enabled by HK2, methylation calling with PacBio HiFi sequencing is poised to set a new standard for accuracy in the industry, surpassing other available technologies.” CUHK, ...

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results: Q1 2025 ...

MENLO PARK, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced it plans to improve on its ...

MENLO PARK, Calif. - Pacific Biosciences (NASDAQ:PACB), a $324.66 million market cap company trading near its 52-week low, has announced a licensing agreement with The Chinese University of Hong ...

Gene sequencing equipment maker PacBio plans to cut around 120 jobs and lower expenses due to fresh tariffs and reduced funding for federal health agency National Institutes of Health (NIH), it ...

PacBio总裁兼首席执行官Christian Henry表示：“Vega实现了我们的愿景，即扩大我们先进测序技术的使用范围，在一个紧凑的系统中实现经济性和精确性。这款产品是我们致力于创新和创造满足研究界多样化需求的解决方案的直接成果。

Pacific Biosciences, Inc. PACB, popularly known as PacBio, has signed a new Research Collaboration Agreement with the National Cancer Centre of Singapore (NCCS) to enhance Asian cancer research.

有关串联重复的知识点也可以参考PacBio公众号文章测序学院｜串联重复。 基因有限公司作为PacBio公司中国区合作伙伴，自2011年以来将PacBio第三代单分子实时测序技术引入国内，一直为国内用户提供专业的三代测序系统的安装培训，技术支持，应用培训与售后维护工作，赢得客户的一致好评与信任。